[1P] 69 Alzheimer's Disease and Dementia

[1P-327] Genetic and Pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairments and synaptotoxicity in a preclinical model of Alzheimer’s disease

*SHINSUKE MATSUZAKI^1,2,3, Nadeeja Wijesekara^4,9, Elentina K. Argyrousi⁵, Hironori Takamura^3,4, Kanayo Satoh⁴, Agnieszka Staniszewski⁵, Erica Acquarone⁵, Taiichi Katayama³, Ottavio Arancio^5,6, Luana Fioriti^5,7, Paul E. Fraser^4,8 (1. Morinomiya University of Medical Science, 2. MINCL, Morinomiya University of Medical Sciences, Osaka, Japan, 3. United Graduate School of Child Development, Osaka University Osaka, Japan, 4. Tanz Centre for Research in Neurode¬¬generative Diseases University of Toronto, Toronto, Ontario , 5. Taub Institute for Research of Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, 6. Department of Medicine, Columbia University, New York, NY, 7. Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, IRCCS, 8. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, 9. Ionis Pharmaceuticals, Carlsbad, CA)

Keywords:Small Ubiquitin-like Modifiers, SUMOylation, amyloid transgenic mouse model, biologic therapy